Seven Eight Capital, LP Aerie Pharmaceuticals Inc Transaction History

Seven Eight Capital, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 12, 2019	SELL	$28.97 - $48.21 $1.38 Million - $2.29 Million	-47,600 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$36.32 - $49.25 $1.29 Million - $1.74 Million	35,400 Added 290.16%	47,600 $2.26 Million
Q4 2018 Feb 14, 2019	SELL	$33.0 - $60.04 $471,900 - $858,572	-14,300 Reduced 53.96%	12,200 $440,000
Q3 2018 Oct 18, 2018	BUY	$56.15 - $73.9 $1.49 Million - $1.96 Million	26,500 New	26,500 $1.63 Million
Q3 2017 Oct 16, 2017	SELL	$48.6 - $60.1 $272,160 - $336,560	-5,600 Closed	0 $0
Q2 2017 Aug 10, 2017	BUY	N/A	5,600	5,600 $294,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.